Murchinson Ltd. Reduces Stock Position in Amedisys, Inc. (NASDAQ:AMED)

Murchinson Ltd. cut its holdings in Amedisys, Inc. (NASDAQ:AMED) by 6.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 68,330 shares of the health services provider’s stock after selling 4,933 shares during the quarter. Amedisys makes up approximately 1.2% of Murchinson Ltd.’s holdings, making the stock its 12th largest holding. Murchinson Ltd. owned about 0.21% of Amedisys worth $6,273,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. BNP Paribas Financial Markets increased its position in Amedisys by 74.0% during the 4th quarter. BNP Paribas Financial Markets now owns 5,692 shares of the health services provider’s stock valued at $541,000 after purchasing an additional 2,421 shares during the period. Norges Bank purchased a new position in shares of Amedisys during the fourth quarter valued at about $34,032,000. Hilltop Holdings Inc. purchased a new position in shares of Amedisys during the fourth quarter valued at about $2,001,000. Allianz Asset Management GmbH raised its stake in Amedisys by 146.0% in the fourth quarter. Allianz Asset Management GmbH now owns 39,855 shares of the health services provider’s stock worth $3,789,000 after buying an additional 23,655 shares in the last quarter. Finally, Olympiad Research LP lifted its holdings in Amedisys by 31.1% in the fourth quarter. Olympiad Research LP now owns 20,942 shares of the health services provider’s stock worth $1,991,000 after buying an additional 4,974 shares during the period. Hedge funds and other institutional investors own 94.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on AMED shares. William Blair downgraded Amedisys from an “outperform” rating to a “market perform” rating in a report on Monday, July 1st. Deutsche Bank Aktiengesellschaft downgraded Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price objective for the company. in a report on Monday, July 29th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $101.00 target price on shares of Amedisys in a report on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat, Amedisys presently has an average rating of “Hold” and a consensus target price of $100.67.

Amedisys Stock Performance

Amedisys stock opened at $96.87 on Tuesday. Amedisys, Inc. has a twelve month low of $89.55 and a twelve month high of $98.95. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $3.17 billion, a P/E ratio of -151.36, a PEG ratio of 1.89 and a beta of 0.78. The stock’s 50 day moving average is $97.67 and its 200 day moving average is $94.87.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings results on Wednesday, July 24th. The health services provider reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.10. The firm had revenue of $591.19 million during the quarter, compared to the consensus estimate of $579.34 million. Amedisys had a return on equity of 12.39% and a net margin of 4.02%. On average, equities research analysts predict that Amedisys, Inc. will post 4.66 earnings per share for the current fiscal year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.